Duncan Mackie is originally from Fort Lauderdale, Fla. In 2006, Mackie earned his Bachelor of Science in mathematics from the University of the Cumberlands in Williamsburg, Ky. He continued his studies in biology and chemistry in 2008, during which time he was a 14-time All-American as a member of the university's swimming and diving team.
Upon graduation he joined the University of South Florida in Tampa as an academic coach to the football team where he mentored college athletes in the hopes of preparing them for future success. It was during this time he became interested in obtaining his advanced degree and a career in academia.
In 2009, he joined the University of Iowa's Department of Pharmaceutical Sciences and Experimental Therapeutics as a doctoral candidate. As a member of the Division of Medicinal and Natural Products Chemistry, he worked with Associate Professor David L. Roman. During the course of his graduate studies, Mackie was extremely productive. He was named an author on several manuscripts as well as producing two provisional patents for his discovery of the first RGS17 small molecule inhibitors. This work lead to him being named an NIH Pre-doctoral Fellow on the Center of Biocatalysis and Bioprocessing T32 training grant and the American Foundation for Pharmaceutical Education (AFPE) Pre-doctoral Fellowship in Pharmaceutical Science. While at the University of Iowa, Mackie was a member of the Prostate Cancer Research Program and a training member of the Holden Comprehensive Cancer Center.
Upon graduation in 2014, Mackie joined the University of North Carolina at Chapel Hill as a post-doctoral research associate in the Department of Cellular Biology and Physiology. As a member of this high profile department, Mackie is working with Professor Kathleen Caron applying the principles of medicinal chemistry and pharmacology, which he learned at the University of Iowa, to understand the complex signaling underlying disease states.